File(s) under permanent embargo
Heparins in ulcerative colitis: proposed and potential reasons for inconsistent clinical outcomes
journal contributionposted on 2023-05-18, 12:23 authored by Lean, QY, Nuri GuvenNuri Guven, Rajaraman Eri, Bhatia, R, Sukhwinder SohalSukhwinder Sohal, Niall Stewart, Gregory PetersonGregory Peterson, Rahul PatelRahul Patel
Current drug therapies for ulcerative colitis (UC) are not completely effective in managing moderate-to-severe UC and approximately 20% of patients with severe UC require surgical interventions. Heparins, polydisperse mixtures of non-anticoagulant and anticoagulant oligosaccharides, are widely used as anticoagulants. However, heparins are also reported to have anti-inflammatory properties. Unfractionated heparin was initially used in patients with UC for the treatment of rectal microthrombi. Surprisingly, it was found to be effective in reducing UC-associated symptoms. Since then, several pre-clinical and clinical studies have reported promising outcomes of heparins in UC. In contrast, some controlled clinical trials demonstrated no or only limited benefits, thus the potential of heparins for the treatment of UC remains uncertain. This review discusses potential mechanisms of action of heparins, as well as proposed reasons for their contradictory clinical effectiveness in the treatment of UC.
Publication titleExpert Review of Clinical Pharmacology
Department/SchoolSchool of Pharmacy and Pharmacology
PublisherExpert Reviews Ltd.
Place of publicationUnited Kingdom
Rights statement© 2015 Taylor & Francis